Document Detail


The role of metformin in the management of polycystic ovary syndrome.
MedLine Citation:
PMID:  14624214     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
PURPOSE OF REVIEW: The purpose of this review is to provide a critical summary of recent studies on the clinical effects of metformin in polycystic ovary syndrome. RECENT FINDINGS: After the recognition that hyperinsulinaemia is a fundamental disturbance in polycystic ovary syndrome, a novel and promising form of therapy in the form of insulin-sensitizing drugs has been introduced. Among these, metformin is the most widely used. This therapeutic intervention has been shown to exert beneficial effects on the endocrine and metabolic disturbances that characterize the syndrome and, more recently, to improve the reproductive outcome in women with polycystic ovary syndrome. With rapid progress in this area, metformin use has also been extended to the management of lean polycystic ovary syndrome patients. SUMMARY: Although most studies are nonrandomized trials, current data provide a rationale for metformin as first-line management for women with polycystic ovary syndrome, alone or in combination with conventional treatments. Controversy still exists, however, regarding the mechanisms by which metformin exerts its beneficial effects in polycystic ovary syndrome.
Authors:
Tasoula Tsilchorozidou; Gordana M Prelevic
Related Documents :
9855614 - Polycystic ovary syndrome: symptomatology, pathophysiology, and epidemiology.
8374664 - Polycystic ovary syndrome.
8140684 - Youssef's syndrome: an appraisal of hormonal treatment.
1342854 - Acrorenal syndrome: further observations.
2403814 - Fragile x syndrome.
12358664 - Morquio's syndrome and its anaesthetic considerations.
Publication Detail:
Type:  Journal Article    
Journal Detail:
Title:  Current opinion in obstetrics & gynecology     Volume:  15     ISSN:  1040-872X     ISO Abbreviation:  Curr. Opin. Obstet. Gynecol.     Publication Date:  2003 Dec 
Date Detail:
Created Date:  2003-11-18     Completed Date:  2004-08-10     Revised Date:  2004-11-17    
Medline Journal Info:
Nlm Unique ID:  9007264     Medline TA:  Curr Opin Obstet Gynecol     Country:  England    
Other Details:
Languages:  eng     Pagination:  483-8     Citation Subset:  IM    
Affiliation:
Department of Medicine, Royal Free and University College London Medical School, The Middlesex Hospital, UK.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Female
Humans
Hypoglycemic Agents / pharmacology,  therapeutic use*
Insulin Resistance / physiology
Metformin / pharmacology,  therapeutic use*
Polycystic Ovary Syndrome / drug therapy*,  physiopathology
Reproduction / drug effects
Chemical
Reg. No./Substance:
0/Hypoglycemic Agents; 657-24-9/Metformin

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Current concepts regarding vaginal birth after cesarean delivery.
Next Document:  Post Magpie: how should we be managing severe preeclampsia?